Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...

Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

Weight loss injectables such as Ozempic and Mounjaro are gaining popularity in India But are they a sustainable solution or a ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

While Mounjaro offers clinicians a newer option for patients, themedicine alone is not a solution. (Photo: Getty Images) Mounjaro enters India as weight-loss drug, but doctors warn against misuse ...

India's weight-loss game is getting serious! The country's anti-obesity market is now worth ₹628 crore, and it's climbing ...

Indian pharmaceutical firms are gearing up to capitalize on the growing demand for weight-loss drugs, with the market potentially reaching $1bn.

Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May, with the drug logging a 60% rise in overall sales between April and May ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Vials of Eli Lilly's Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and weight loss, are seen in a fridge at a health clinic in Hyderabad, India, April 14, 2025.